Back to Sites

Molepolole CRS

Site Number

12702

Address

Molepolole Prevention/Treatment Trials CRS
Scottish Livingstone Hospital
Gaborone-Molepolole Road
Molepolole,
Botswana

IMPAACT Members at this Site

Chenesani Bohule Clinical Research Assistant

Ayotunde Omoz-Oarhe Co-Investigator

Ponego Ponatshego CRS Coordinator

Mpho Raesi CRS Coordinator

Akeem Salawu CRS Coordinator

Gaerolwe Masheto CRS Leader

Ayotunde Omoz-Oarhe CRS Leader

Gaerolwe Masheto CTU Coordinator

Shahin Lockman CTU Principal Investigator

Joseph Moeketsi Makhema CTU Principal Investigator

Sue A. Welsch DAIDS PO

Farida Monggae Data Manager

Masego Rankowa Data Manager

Rasak Abdullahi Investigator

Unoda Chakalisa Investigator

Kenneth Maswabi Investigator

Sikhulile Moyo Laboratory Manager/Supervisor

Lesedi Tirelo Laboratory QA/QC Coordinator

Motswedi Anderson Laboratory Technician/Technologist

Rufaro L. Mangwarara Pharmacist

Tshepho Theodorah Frank Pharmacy Supervisor

Urunduruka Mavis Munamava QA/QC Coordinator

Tumalano Sekoto Regulatory Coordinator

Tebogo Kakhu Staff

Tebogo Mokotedi Staff

Kelechi Edgar Nnajide Staff

Anthony Chibuzor Ogwu Staff

Studies at this Site

1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)

DAIDS Number

10779

Research Area

Prevention

Study Status

Participants Off Study and Primary Analysis Completed

P1026S: PK in Pregnancy

DAIDS Number

10040

Research Area

Treatment

Study Status

Closed to Follow Up

P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers

DAIDS Number

10638

Research Area

Complications & Comorbidities

Study Status

Concluded

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

10732

Research Area

Tuberculosis

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Treatment

Study Status

Closed to Accrual

IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV

DAIDS Number

20721

Research Area

Tuberculosis

Study Status

Enrolling

IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

DAIDS Number

20735

Research Area

Cure

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Complications & Comorbidities

Study Status

Open to Accrual

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed